IL6 and COVID-19: Consistent with earlier studies, such as the RECOVERY trial [62, 63], our results demonstrate that IL-6 levels are significantly higher in COVID-19 patients with pneumonia compared with those without pneumonia, and also compared with healthy controls, confirming its role in exacerbating hyperinflammatory responses.